 |
|
Minocycline-Induced Hyperpigmentation in Patients With Pemphigus and Pemphigoid
David M. Ozog;
Darin S. Gogstetter, MD;
Glynis Scott, MD;
Anthony A. Gaspari, MD
Arch Dermatol. 2000;136:1133-1138.
Background Immunosuppressive medications typically used to treat the immunobullous disorders pemphigus vulgaris, pemphigus foliaceous, and bullous pemphigoid can have serious adverse effects. The tetracycline family of antibiotic drugs has been shown to be effective in the treatment of these conditions with a more favorable side effect profile. Minocycline hydrochloride use has been associated with various forms of hyperpigmentation, and its incidence is well reported in acne vulgaris and rheumatoid arthritis. We examined a series of 9 patients treated with minocycline for pemphigus or pemphigoid, most of whom have developed cutaneous hyperpigmentation.
Observations Seven of 9 patients treated with minocycline, 50 mg daily (1 patient) or 100 mg twice daily (8 patients), for pemphigus vulgaris, pemphigus foliaceous, or bullous pemphigoid developed hyperpigmentation, which necessitated discontinuing therapy. Five of these patients had experienced notable clinical improvement of their immunobullous disease with minocycline therapy. The average duration of treatment was 8.2 months (range, 1-25 months). The second most common adverse effect in our group was oral candidiasis, which occurred in 2 patients.
Conclusions We found a favorable response to minocycline therapy in 5 of 9 patients. However, 7 patients developed localized hyperpigmentation as early as 1 month after starting medication use. This incidence of minocycline-induced hyperpigmentation is significantly higher in immunobullous disease than in acne vulgaris or rheumatoid arthritis. This increased incidence may be related to an increase in pigment deposition complexed with collagen during the remodeling process, subclinical inflammation, or glucocorticosteroid-induced skin fragility. The hyperpigmentation process was reversible, as most of our patients had fading of their pigmentation after minocycline cessation.
From the Departments of Dermatology (Drs Gogstetter, Scott, and Gaspari), Microbiology/Immunology (Dr Gaspari), and the Cancer Center (Dr Gaspari), University of Rochester School of Medicine and Dentistry, Rochester, NY. Mr Ozog was a medical student at the time of this study.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED ARTICLE
Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 2000;136(9):1182-1183.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Minocycline-Induced Blue-Green Discoloration of Bone. A Case Report
McCleskey and Littleton
JBJS 2004;86:146-148.
FULL TEXT
Minocycline-Induced Ocular Pigmentation
Bradfield et al.
Arch Ophthalmol 2003;121:144-145.
FULL TEXT
|
